Beyond TLR2, targeting TLR4 with small-molecule inhibitors or neutralizing mAbs has also shown anticancer efficacy, especially in chemically induced models of colitis-associated colon cancer.592 However, the translation of TLR4 inhibitors into clinical practice for cancer treatment has not yet succeeded. This evidence concerns the gene TLR4 and colonic neoplasm.